SLC5A2 and diabetic kidney disease: Recently, members of the newest class of oral glucose-lowering drugs – sodium-glucose cotransporter-2 (SGLT2) inhibitors – appeared to slow the progression of diabetic kidney disease in exploratory analyses of cardiovascular outcomes studies [15,16].